{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:21:46Z","timestamp":1793578906724,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01480-4","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:35:21Z","timestamp":1778740521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia"],"prefix":"10.1038","volume":"10","author":[{"given":"Katarina","family":"Willoch-Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ayuda-Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Mikaeloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nona","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albin","family":"\u00d6sterroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Erkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit M.","family":"Enserink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1480_CR1","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013).","journal-title":"Cancer Discov."},{"key":"1480_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","volume":"73","author":"JW Tyner","year":"2013","unstructured":"Tyner, J. W. et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 73, 285\u2013296 (2013).","journal-title":"Cancer Res"},{"key":"1480_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"1480_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.tips.2022.08.009","volume":"43","author":"\u00c5 Flobak","year":"2022","unstructured":"Flobak, \u00c5, Sk\u00e5nland, S. S., Hovig, E., Task\u00e9n, K. & Russnes, H. G. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends Pharmacol. Sci. 43, 973\u2013985 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"1480_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"1480_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26\u201335 (2022).","journal-title":"Cancer Cell"},{"key":"1480_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"1480_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood.2024024968","volume":"145","author":"S Kyt\u00f6l\u00e4","year":"2025","unstructured":"Kyt\u00f6l\u00e4, S. et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. Blood 145, 409\u2013421 (2025).","journal-title":"Blood"},{"key":"1480_CR9","doi-asserted-by":"publisher","unstructured":"Tomska, K. et al. Lymphoma and leukemia cell vulnerabilities and resistance identified by compound library screens. in Lymphoma: Methods and Protocols (ed. K\u00fcppers, R.) 259\u2013272 (Springer, 2019). https:\/\/doi.org\/10.1007\/978-1-0716-4188-0_11","DOI":"10.1007\/978-1-0716-4188-0_11"},{"key":"1480_CR10","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"1480_CR11","first-page":"100654","volume":"3","author":"AN Andersen","year":"2023","unstructured":"Andersen, A. N. et al. Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling. Cell Rep. Methods 3, 100654 (2023).","journal-title":"Methods"},{"key":"1480_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","volume":"29","author":"SHR Lee","year":"2023","unstructured":"Lee, S. H. R. et al. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. Nat. Med. 29, 170\u2013179 (2023).","journal-title":"Nat. Med."},{"key":"1480_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/d41586-024-00392-2","volume":"626","author":"E Dolgin","year":"2024","unstructured":"Dolgin, E. The future of precision cancer therapy might be to try everything. Nature 626, 470\u2013473 (2024).","journal-title":"Nature"},{"key":"1480_CR14","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/0008-5472.CAN-24-3840","volume":"85","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. Cancer Res 85, 2753\u20132768 (2025).","journal-title":"Cancer Res"},{"key":"1480_CR15","doi-asserted-by":"publisher","first-page":"e70129","DOI":"10.1002\/hem3.70129","volume":"9","author":"L Kazianka","year":"2025","unstructured":"Kazianka, L. et al. Comparing functional and genomic-based precision medicine in blood cancer patients. HemaSphere 9, e70129 (2025).","journal-title":"HemaSphere"},{"key":"1480_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature12831","volume":"504","author":"B Haibe-Kains","year":"2013","unstructured":"Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389\u2013393 (2013).","journal-title":"Nature"},{"key":"1480_CR17","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-14-0725","volume":"74","author":"C Hatzis","year":"2014","unstructured":"Hatzis, C. et al. Enhancing reproducibility in cancer drug screening: how do we move forward?. Cancer Res 74, 4016\u20134023 (2014).","journal-title":"Cancer Res"},{"key":"1480_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","volume":"9","author":"M Niepel","year":"2019","unstructured":"Niepel, M. et al. A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. Cell Syst. 9, 35\u201348.e35 (2019).","journal-title":"Cell Syst."},{"key":"1480_CR19","doi-asserted-by":"publisher","first-page":"106671","DOI":"10.1016\/j.phrs.2023.106671","volume":"188","author":"IG Reddin","year":"2023","unstructured":"Reddin, I. G., Fenton, T. R., Wass, M. N. & Michaelis, M. Large inherent variability in data derived from highly standardised cell culture experiments. Pharmacol. Res. 188, 106671 (2023).","journal-title":"Pharmacol. Res."},{"key":"1480_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature17987","volume":"533","author":"PM Haverty","year":"2016","unstructured":"Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333\u2013337 (2016).","journal-title":"Nature"},{"key":"1480_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cpch.21","volume":"9","author":"M Niepel","year":"2017","unstructured":"Niepel, M., Hafner, M., Chung, M. & Sorger, P. K. Measuring cancer drug sensitivity and resistance in cultured cells. Curr. Protoc. Chem. Biol. 9, 55\u201374 (2017).","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"1480_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62848-5","volume":"10","author":"P Larsson","year":"2020","unstructured":"Larsson, P. et al. Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. Sci. Rep. 10, 5798 (2020).","journal-title":"Sci. Rep."},{"key":"1480_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen, R. et al. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell\u2013induced protection of AML. Blood 130, 789\u2013802 (2017).","journal-title":"Blood"},{"key":"1480_CR24","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108, 1768 (2023).","journal-title":"Haematologica"},{"key":"1480_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/biostatistics\/kxac010","volume":"24","author":"M Ploenzke","year":"2022","unstructured":"Ploenzke, M. & Irizarry, R. Reassessing pharmacogenomic cell sensitivity with multilevel statistical models. Biostatistics 24, 901\u2013921 (2022).","journal-title":"Biostatistics"},{"key":"1480_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ccell.2022.01.015","volume":"40","author":"C-P Day","year":"2022","unstructured":"Day, C.-P. et al. Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies. Cancer Cell 40, 231\u2013232 (2022).","journal-title":"Cancer Cell"},{"key":"1480_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00583-0","volume":"8","author":"K Ovchinnikova","year":"2024","unstructured":"Ovchinnikova, K., Born, J., Chouvardas, P., Rapsomaniki, M. & Kruithof-de Julio, M. Overcoming limitations in current measures of drug response may enable AI-driven precision oncology. NPJ Precis. Oncol. 8, 95 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"1480_CR28","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1038\/nature20171","volume":"540","author":"JP Mpindi","year":"2016","unstructured":"Mpindi, J. P. et al. Consistency in drug response profiling. Nature 540, E5\u2013E6 (2016).","journal-title":"Nature"},{"key":"1480_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41596-023-00903-x","volume":"19","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Robust scoring of selective drug responses for patient-tailored therapy selection. Nat. Protoc. 19, 60\u201382 (2024).","journal-title":"Nat. Protoc."},{"key":"1480_CR30","doi-asserted-by":"publisher","first-page":"27786","DOI":"10.18632\/oncotarget.15347","volume":"8","author":"K-F Ding","year":"2017","unstructured":"Ding, K.-F. et al. Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget 8, 27786 (2017).","journal-title":"Oncotarget"},{"key":"1480_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","journal-title":"J. Stat. Softw."},{"key":"1480_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","volume":"85","author":"BA Roecklein","year":"1995","unstructured":"Roecklein, B. A. & Torok-Storb, B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes. Blood 85, 997\u20131005 (1995).","journal-title":"Blood"},{"key":"1480_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00528-7","volume":"8","author":"N Struyf","year":"2024","unstructured":"Struyf, N. et al. Delineating functional and molecular impact of ex vivo sample handling in precision medicine. NPJ Precis. Oncol. 8, 38 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"1480_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"1480_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1128\/CVI.00161-07","volume":"15","author":"C Nilsson","year":"2008","unstructured":"Nilsson, C. et al. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin. Vaccin. Immunol. 15, 585\u2013589 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1480_CR36","doi-asserted-by":"publisher","first-page":"e50293","DOI":"10.1371\/journal.pone.0050293","volume":"7","author":"C P\u00f6sel","year":"2012","unstructured":"P\u00f6sel, C. et al. Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS ONE 7, e50293 (2012).","journal-title":"PLoS ONE"},{"key":"1480_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/bio.2015.0104","volume":"14","author":"HW Grievink","year":"2016","unstructured":"Grievink, H. W., Luisman, T., Kluft, C., Moerland, M. & Malone, K. E. Comparison of three isolation techniques for human peripheral blood mononuclear cells: cell recovery and viability, population composition, and cell functionality. Biopreserv. Biobank. 14, 410\u2013415 (2016).","journal-title":"Biopreserv. Biobank."},{"key":"1480_CR38","doi-asserted-by":"crossref","unstructured":"Hu, Z. T., Ye, Y., Newbury, P. A., Huang, H. & Chen, B. AICM: a genuine framework for correcting inconsistency between large pharmacogenomics datasets. in Proceedings of the Pacific Symposium on Biocomputing 248-259 (World Scientific, 2018).","DOI":"10.1142\/9789813279827_0023"},{"key":"1480_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73503-4","volume":"10","author":"VT Von Kortzfleisch","year":"2020","unstructured":"Von Kortzfleisch, V. T. et al. Improving reproducibility in animal research by splitting the study population into several \u2018mini-experiments\u2019. Sci. Rep. 10, 16579 (2020).","journal-title":"Sci. Rep."},{"key":"1480_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41420-023-01722-5","volume":"9","author":"P Ayuda-Dur\u00e1n","year":"2023","unstructured":"Ayuda-Dur\u00e1n, P. et al. Standardized assays to monitor drug sensitivity in hematologic cancers. Cell Death Discov. 9, 435 (2023).","journal-title":"Cell Death Discov."},{"key":"1480_CR41","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1080\/02664763.2021.1969342","volume":"49","author":"YC Lee","year":"2022","unstructured":"Lee, Y. C. & Shang, J. Estimation and selection in linear mixed models with missing data under compound symmetric structure. J. Appl. Stat. 49, 4003\u20134027 (2022).","journal-title":"J. Appl. Stat."},{"key":"1480_CR42","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrg2825","volume":"11","author":"JT Leek","year":"2010","unstructured":"Leek, J. T. et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 11, 733\u2013739 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"1480_CR43","doi-asserted-by":"publisher","unstructured":"Emman\u00fael Antonsson, S. & Melsted, P. Batch correction methods used in single cell RNA-sequencing analyses are often poorly calibrated. bioRxiv, 2024.2003.2019.585562 https:\/\/doi.org\/10.1101\/2024.03.19.585562 (2024).","DOI":"10.1101\/2024.03.19.585562"},{"key":"1480_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12859-020-03559-6","volume":"21","author":"T Zindler","year":"2020","unstructured":"Zindler, T., Frieling, H., Neyazi, A., Bleich, S. & Friedel, E. Simulating ComBat: how batch correction can lead to the systematic introduction of false positive results in DNA methylation microarray studies. BMC Bioinform 21, 271 (2020).","journal-title":"BMC Bioinform"},{"key":"1480_CR45","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"1480_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0004563216674030","volume":"54","author":"MF M\u00f8ller","year":"2017","unstructured":"M\u00f8ller, M. F., S\u00f8ndergaard, T. R., Kristensen, H. T. & M\u00fcnster, A.-M. B. Evaluation of a reduced centrifugation time and higher centrifugal force on various general chemistry and immunochemistry analytes in plasma and serum. Ann. Clin. Biochem. 54, 593\u2013600 (2017).","journal-title":"Ann. Clin. Biochem."},{"key":"1480_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.11613\/BM.2018.010704","volume":"28","author":"J Cadamuro","year":"2018","unstructured":"Cadamuro, J. et al. Influence of centrifugation conditions on the results of 77 routine clinical chemistry analytes using standard vacuum blood collection tubes and the new BD-Barricor tubes. Biochem. Med. 28, 55\u201364 (2018).","journal-title":"Biochem. Med."},{"key":"1480_CR48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tips.2017.06.005","volume":"38","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Delavan, B., Roberts, R. & Tong, W. Lessons learned from two decades of anticancer drugs. Trends Pharmacol. Sci. 38, 852\u2013872 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"1480_CR49","doi-asserted-by":"publisher","first-page":"e63583","DOI":"10.1371\/journal.pone.0063583","volume":"8","author":"GKY Chan","year":"2013","unstructured":"Chan, G. K. Y., Kleinheinz, T. L., Peterson, D. & Moffat, J. G. A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS ONE 8, e63583 (2013).","journal-title":"PLoS ONE"},{"key":"1480_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1480_CR51","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850\u2013864.e859 (2022).","journal-title":"Cancer Cell"},{"key":"1480_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 1\u201310 (2014).","journal-title":"Sci. Rep."},{"key":"1480_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1109\/34.667885","volume":"20","author":"CM Bishop","year":"1998","unstructured":"Bishop, C. M. & Tipping, M. E. A hierarchical latent variable model for data visualization. IEEE Trans. Pattern Anal. Mach. Intell. 20, 281\u2013293 (1998).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"1480_CR54","first-page":"60","volume":"3","author":"N Iyit","year":"2009","unstructured":"Iyit, N. & Genc, A. Constitution of linear mixed models (LMMs) in the analysis of correlated data: random intercept model (RIM) for repeated measurements data. J. Mod. Math. Stat. 3, 60\u201368 (2009).","journal-title":"J. Mod. Math. Stat."},{"key":"1480_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2517-6161.1964.tb00553.x","volume":"26","author":"GEP Box","year":"2018","unstructured":"Box, G. E. P. & Cox, D. R. An Analysis of Transformations. J. R. Stat. Soc. B 26, 211\u2013243 (2018).","journal-title":"J. R. Stat. Soc. B"},{"key":"1480_CR56","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.21105\/joss.03139","volume":"6","author":"D L\u00fcdecke","year":"2021","unstructured":"L\u00fcdecke, D., Ben-Shachar, M. S., Patil, I., Waggoner, P. & Makowski, D. Performance: An R package for assessment, comparison and testing of statistical models. J. Open Source Softw. 6, 3139 (2021).","journal-title":"J. Open Source Softw."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01480-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:03:15Z","timestamp":1785517395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01480-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01480-4","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author J.W.T. is an Associate Editor of npj Precision Oncology. J.W.T. was not involved in the journal\u2019s review of, or decisions related to, this manuscript. The authors declare the following competing financial interests: O.K. is a co-founder and a board member of Sartar Therapeutics and acts as a scientific advisor to the Knut and Alice Wallenberg Foundation as well as the Novo Nordisk Foundation (all unrelated to the topics of this study). J.W.T. received research support from Acerta, Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Kronos, Meryx, Petra, Schrodinger, Seattle Genetics, Syros, Takeda, and Tolero and serves on the advisory board for Recludix Pharm, AmMax Bio, and Ellipses Pharma. T.A. has received unrelated research funding from Mobius Biotechnology GmbH. The rest of the authors declare no Competing Financial or Non-Financial Interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"294"}}